오젬픽 시장 규모, 점유율, 동향 및 성장 분석 보고서( 2026-2034년)

The global Ozempic market size is expected to reach USD 196.23 Billion in 2034 from USD 26.30 Billion in 2025, growing at a CAGR of 25.02 during 2026-2034.This market is witnessing remarkable growth due to the increasing prevalence of type 2 diabetes and obesity worldwide. Ozempic has gained strong recognition for its effectiveness in blood sugar management and weight reduction, leading to rising adoption among healthcare providers and patients. Growing awareness regarding chronic disease management and advancements in pharmaceutical research are significantly contributing to market expansion.

Rising healthcare expenditures and increasing focus on obesity treatment are major factors driving global demand for Ozempic. Healthcare professionals are increasingly recommending GLP-1 receptor agonists due to their therapeutic benefits and improved patient outcomes. Pharmaceutical companies are also investing heavily in research and development activities to expand treatment applications and improve drug accessibility across various healthcare systems.

The future outlook for the market remains highly optimistic as demand for advanced diabetes and weight management therapies continues to rise. Expanding healthcare infrastructure in emerging economies and ongoing clinical research are expected to support long-term market growth. Technological innovations in drug delivery systems and increasing insurance coverage for chronic disease treatments are likely to further strengthen market adoption globally.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Indication

• Type-2 Diabetes
• Obesity / Weight Management
• Cardiovascular-Risk-Reduction (Anticipated)
• Other Emerging Uses

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online / Mail-Order Pharmacies
• Tele-health Platforms

COMPANIES PROFILED

• Novo Nordisk, Eli Lilly and Company, AstraZeneca PLC, Sanofi, Boehringer Ingelheim, Hanmi Pharmaceutical, Hansoh Pharmaceutical, Viking Therapeutics, Lexicon Pharmaceuticals, Biocon, Zydus Lifesciences, Sun Pharmaceutical Industries, Cipla, Torrent Pharmaceuticals, Viatris

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL OZEMPIC MARKET: BY INDICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Indication
• 4.2. Type-2 Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Obesity / Weight Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cardiovascular-Risk-Reduction (Anticipated) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Other Emerging Uses Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL OZEMPIC MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Online / Mail-Order Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Tele-health Platforms Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL OZEMPIC MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Indication
  • 6.2.2 By Distribution Channel
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Indication
  • 6.3.2 By Distribution Channel
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Indication
  • 6.4.2 By Distribution Channel
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Indication
  • 6.5.2 By Distribution Channel
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Indication
  • 6.6.2 By Distribution Channel
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL OZEMPIC INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Novo Nordisk
  • 8.2.2 Eli Lilly And Company
  • 8.2.3 AstraZeneca PLC
  • 8.2.4 Sanofi
  • 8.2.5 Boehringer Ingelheim
  • 8.2.6 Hanmi Pharmaceutical
  • 8.2.7 Hansoh Pharmaceutical
  • 8.2.8 Viking Therapeutics
  • 8.2.9 Lexicon Pharmaceuticals
  • 8.2.10 Biocon
  • 8.2.11 Zydus Lifesciences
  • 8.2.12 Sun Pharmaceutical Industries
  • 8.2.13 Cipla
  • 8.2.14 Torrent Pharmaceuticals
  • 8.2.15 Viatris